Solifenacin in the treatment of overactive bladder syndrome in Italian patients: pharmacoeconomic evaluation

References

• Abrams P, Cardozo L, Fall M et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology 2003;61:37–49.
   PubMed Web of Science ®Google Scholar
• Abrams P, Kelleher CJ, Kerr LA, Rogers RG. Overactive bladder significantly affects quality of life. Am J Manag Care 2000; 6(Suppl 11):S580–S590.
   PubMed Web of Science ®Google Scholar
• Coyne KS, Payne C, Bhattacharyya SK et al. The impact of urinary urgency and frequency on health-related quality of life in overactive bladder: results from a national community survey. Value Health 2004;7:455–463.
   PubMed Web of Science ®Google Scholar
• Milsom I, Abrams P, Cardozo L et al. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 2001; 87:760–766.
   PubMed Web of Science ®Google Scholar
• Stewart W, Herzog R, Wein A et al. Prevalence and impact of overactive bladder in the US. Results from the NOBLE program. International Continence Society Meeting, Seoul, Korea, 2001; abstract 24.
   Google Scholar
• Versi E. Screening initiative confirms widespread prevalence of overactive bladder in American adults. Int Urogynecol J 2001; 12:S13.
   Google Scholar
• Epstein BJ, Gums JG, Molina E. Newer agents for the management of overactive bladder. Am Fam Physician 2006; 74:2061–2068.
   PubMed Web of Science ®Google Scholar
• Chapple CR, Rechberger T, Al-Shukri S et al. Randomized, double-blind placebo and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int 2004;93:303–310.
   PubMed Web of Science ®Google Scholar
• Cardozo L, Lisec M, Millard R et al. Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J Urol 2004;172:1919–1924.
   PubMed Web of Science ®Google Scholar
• Van Kerrebroeck P, Kreder K, Jonas U et al, on behalf of the Tolterodine Study Group. Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder. Urology 2001;54:414–421.
   Google Scholar
• Chapple CR, Fianu-Jonsson A, Indig M et al, for the STAR study group. Treatment outcomes in the STAR study: a subanalysis of solifenacin 5 mg and tolterodine ER 4 mg. Eur Urol 2007; 52:1195–1203.
   PubMed Web of Science ®Google Scholar
• Chapple CR, Martinez-Garcia R, Selvaggi L et al. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results from the STAR trial. Eur Urol 2005;48:464–470.
   PubMed Web of Science ®Google Scholar
• Vesiker®, Riassunto delle Caratteristiche del Prodotto.
   Google Scholar
• Haab F, Cardozo L, Chapple C, Ridder AM; Solifenacin Study Group. Longterm open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome. Eur Urol 2005;47:376–384.
   PubMed Web of Science ®Google Scholar
• Takei M, Homma Y; the Japanese Tolterodine Study Group. Long-term safety, tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder in Japanese patients. Int J Urol 2005;12(5):456–464.
   PubMedGoogle Scholar
• Homma Y, Paick JS, Lee JG, Kawabe K, on behalf of the Japanese and Korean Tolterodine Study Group. Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo controlled trial. BJU Int 2003;92:741–747.
   PubMed Web of Science ®Google Scholar
• Milsom I, Wickstrom J, Poulsen PB. Cost-effectiveness analysis of solifenacin flexible dosing in patients with overactive bladder symptoms in four Nordic countries. Value Health 2006;9(6):A389.
   Google Scholar
• Thorpe A, Terry T, Fynes M et al. A cost/utility analysis of solifenacin 5 mg versus tolterodine ER 4 mg. Urology 2007;70(3A):87.
   Google Scholar
• Kobelt G, Jonsson L, Mattiasson A. Cost/effectiveness of new treatments for overactive bladder: the example of tolterodine, a new muscarinic agent: a Markov model. Neurourol Urodyn 1998;17:599–611.
   PubMed Web of Science ®Google Scholar
• Johanneson M, O'Connor RM, Kobelt G, Mattiasson A. Willingness to pay for reduced incontinence symptoms. Br J Urol 1997;80:557–562.
   PubMedGoogle Scholar
• Currie CJ, McEwan P, Poole CD et al. The impact of the overactive bladder on health-related utility and quality of life. BJU Int 2006;97:1267–1272.
   PubMed Web of Science ®Google Scholar
• Bernasconi F, Grasso M, Mantovani C et al. Social cost of female urinary incontinence: epidemiology, cost of illness and cost/effectiveness analysis. Urogynaecol Int J 2003;17:9–42.
   Google Scholar
• Guglieri A. Ausili assorbenti per incontinenza. CSA – Centro Studi Assobiomedica numero 6 – Maggio 2000.
   Google Scholar
• Garattini L, Castelnuovo E, Lanzeni D, Viscarra C. Durata e costo delle visite in medicina generale: il progetto DYSCO. Farmeconomia e percorsi terapeutici 2003;4(2):109–114.
   Google Scholar
• Decreto Ministeriale 22 luglio 1996. Prestazioni di assistenza specialistica ambulatoriale erogabili nell'ambito del Servizio sanitario nazionale e relative tariffe. (GU n. 216 del 14-9-1996 - Suppl. Ordinario n.150).
   Google Scholar
• Nomenclatore della Regione Piemonte [‘Supplemento Ordinario n. 1 al B.U. n. 36 Deliberazione della Giunta Regionale 26 luglio 2004, n. 73-13176’].
   Google Scholar
• Reeves P, Irwin D, Kheller C et al. The current and future burden and cost of overactive bladder in five European countries. Eur Urol 2006;50:1050–1057.
   PubMed Web of Science ®Google Scholar
• ISTAT. Popolazione residente al 1 gennaio 2006. http:/demo.istat.it/pop2006/index.html. Last accessed 11/28/07.
   Google Scholar
• WHO. CHOosing Interventions that are cost/effective (WHO-CHOICE), 2000. Available at: http:/www.who.int/choice. Last accessed December 2008.
   Google Scholar
• Serie storiche del PIL e dei principali aggregati (Anni 1970-2007). Available at: http:/www.istat.it/conti/. Last accessed December 2008.
   Google Scholar
• Ko Y, Malone DC, Armstrong EP. Pharmacoeconomic evaluation of antimuscarinic agents for the treatment of overactive bladder. Pharmacotherapy 2006;26(12):1694–702.
   PubMedGoogle Scholar
• Speakman M, Khullar V, Mundy A et al. A cost/utility analysis of once daily solifenacin compared to tolterodine in the treatment of overactive bladder syndrome. Curr Med Res Opin 2008;24(8):2173–2179.
   PubMedGoogle Scholar